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A B S T R A C T
The authors report clinical features of ocular manifestations in patients with multiple sclerosis (MS), those that af-
fect the visual sensory system and those that affect the ocular motor system. Disturbances of visual sensory function
may precede, manifest coincidentally or follow the neurologic manifestations. Visual disturbances are common in MS
and often a result of acute demyelinating optic neuropathy. Careful examination of MS patients, who have never suf-
fered optic neuritis, may also reveal asymptomatic visual loss. Asymptomatic visual loss seems to be a universal fea-
ture of MS. Patients with multiple sclerosis may develop disorders of fixation, ocular motility and ocular alignment.
Disorders of ocular motor system are frequently the initial sign of multiple sclerosis and occur as its presenting sign
weeks, month, or years before other neurologic symptoms and signs develop.
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Introduction
Multiple sclerosis is one of the most common causes
of neurologic and visual disability. In general, multiple
sclerosis (MS) manifests itself in the third and fourth
decades, affecting women almost twice as frequently as
men. It has a distinctive geographic and ethnic distribu-
tion that is more likely the result of a geneic predisposi-
tion in Caucasians of northern European descent than a
still completely unknown but indubitable environmen-
tal factor.1
For many years, the diagnosis was based exclusively
on the clinical history and physical examination. Pro-
gressively, what has been termed paraclinical and labo-
ratory tests have been increasingly used. Starting with
the examination of the cerebrospinal fluid and culmi-
nating in the different techniques of magnetic reso-
nance imaging (MRI), the process has been extended
and refined. Unfortunately, none of the diagnostic pro-
cedures is specific for MS, and in some respects, they
make the task more difficult by extending the bound-
aries of differential diagnosis. For instance, the MRI of
many disease of the CNS are indistinguishable from
those frequently seen in MS.1,2
The symptoms and signs caused by MS are many and
varied. They are similar in both sporadic and familial MS
and include neurologic, psychiatric and neuro-ophthal-
mologic manifestations, alone or in combination. The
neuro-ophthalmologic manifestations of multiple sclero-
sis can be divided into two main categories: those that
affect the visual sensory system and those that affect
the ocular motor system.
Visual Sensory Manifestations
Disturbances of visual sensory function caused by
disease of the retina and optic nerve in prechiasmal,
chiasmal and postchiasmal locations. These lesions my
precede, manifests coincidentally or follow the neuro-
logic manifestations. In some cases, disturbances of the
visual sensory system are themselves asymptomatic but
may be important findings that establish the diagnosis
of MS. Visual disturbances occurs in the great procent of
patients with MS.3 A brief review of the various visual
sensory manifestations of multiple sclerosis follows.
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Choroidal and retinal lesions and uveitis
Some authors reported individual cases or series of
periphlebitis, occasionaly associated with posterior uve-
itis, branch retinal occlusion, neovascularization, reti-
nal venous sheathing (included focal venous sheathing,
diffuse venous sheathing and sheathing centered on
sites of arteriovenous crossings) and pars planitis.4,5
Katsimpris et al. (2002) presented the case of a 32-
year-old man suffering from MS who had developed bi-
lateral peripheral neovascularization of the retina.6 The
main disease had been diagnosed 10 years before,
whereas in his ophthalmic history the patient reported
an incident of retrobulbar optic neuritis in his lef eye oc-
curring 3 years before. Ophthalmic examination and
fluorescein angiography revealed the presence of a bi-
lateral peripheral retinal neovascularization with an
intravitreous hemorrhage in the left eye. Systemic clini-
cal and laboratory investigation were negative for other
causes of retinal neovascularization except MS, which is
associated with periphlebitis in l0% of cases. Chronic
retinal ishemia may lead to retinal neovascularization.
Hochwarter et al. (2004) noted vitreoretinal trac-
tions in 2 of 89 patients with MS with signs of peri-
phlebitis before clinical-neurological manifestation of
multiple sclerosis.7 The third patient, in whom the disease
had been known for years, showed distinct neovascu-
larizations, vasculitis, and recurrent vitreous hemor-
rhages. High-dose steroid therapy resulted in stabiliza-
tion of the retinal situation in one patient, but the
tractions remained unchanged. Additional laser coagu-
lation in the second patient achieved stabilization and
reduction of the tractions. A pars plana vitrectomy led to
stabilization of the retinal proliferation in the third pa-
tient. Authors concluded that the vitreoretinal traction
syndrome is associated with MS and can precede its
clinical-neurological manifestation. The good results af-
ter argon laser coagulation and vitreoretinal surgery
suggest a vascular pathogenesis of these tractions.
In some studies, retinal vascular sheathing corre-
lates with severitiy of neurologic dysfunction in patients
with MS; in others, there is no such correlation.4,8 Pa-
thologic evidence of retinal phlebitis is present in higher
percentage of cases than those with ophthalmoscopi-
cally visible abnormalities. Kerrison et al. (1994) exam-
ined the eyes obtained postmortem from 25 patients
with definite MS, one patient with possible MS, and
three patients with neuromyelitis optica. These inves-
tigetors found evidence of retinal in only one of 49 eyes
examined using routine processing. However, when the
retinal vessels were examined after trypsin digestion,
seven of 39 eyes (17,9% of eyes) showed evidence of reti-
nal phlebitis.9 Rodrigues et al. (1995) also found retinal
sheathing to be associated with an increased likelihood
of developing MS in their cohort of 156 patients with op-
tic neuritis.10 Thus, retinal venous sheathing may be a
prognostic indicator of early development of MS.
The frequency of uveitis among patients with MS is
many times that of general population. The uveitis may
be posterior, anterior, or both. In addition, pathologic ev-
idence of uveitis may be found in the eyes of patients
who were never noted to have clinical evidence of intra-
ocular inflammation during life9. However, only a mi-
nority of patients with idiopathic retinal vasculitis have
disseminated CNS lesions characteristic of MS11. Poste-
rior and anterior uveitis occurs in minority of patients
with MS. In some cases, anterior granulomatous uveitis
occurs before clinical signs and symptoms of demyeli-
nating disease are evident. MS should be considered in
the differential diagnosis of a patient (although disease
such a sarcoidosis, tuberculosis, Lyme disease, and sy-
philis), particularly a young woman, who develops uni-
lateral or bilateral granulomatous iridocyclitis.12
Pars planitis is a condition of unknown etiology char-
acterized by intraocular inflammation consisting of cells
and debris in the vitreous, condensation of the vitreous
along the pars plana, and varying degrees of periphle-
bitis. There is usually little or no inflammation in the
anterior chamber. The condition can have numerous
sequele that may threaten vision, including cataract for-
mation, development of epiretinal membrane in the
macula, and cystoid macular edema. Malinowski et al.
(1993) found that 16,2%  6,2% risk of patients with
pars planitis developing MS. Malinowski et al. also
found a strong association of pars planitis with HLA-
-DR2 and the temporal development of MS.13,14 Genetic
predisposition in MS has always been a critical concern
in aetiology and progress of the disease. Kheradvar et
al. (2004) presented relations between human leukocyte
antigen (HLA), optic neuritis (ON) and MS in the Ira-
nian population. These study strongly suggests the as-
sociation among DR2, A23 and B21 allele and the evolu-
tion of ON to MS. High prevalence of A23 and DR2
alleles in clinically definite MS patients compared with
the normal population may suggest an important role
for these alleles in the development of MS. The study
suggests B51 as a protective factor against development
of ON in the normal population.15
Zein et al. (2004) described the clinical characteristic
and course of 16 patients with uveitis associated with
MS. Most patients with MS-associated uveitis were
white females between 20 and 50 years of age. The diag-
nosis of MS preceded the onset of uveitis in 56%, fol-
lowed it in 25%, and was made concurrently in 19% of
the cases. In 94%, the uveitis was bilateral. Pars pla-
nitis was the most frequent form of uveitis in their
study population (81%); concomitant anterior chamber
inflammation was common and was granulomatous in
nature 56% of the time. Forty-one percent of the eyes
with MS-associated uveitis had 20/30 or better initial vi-
sual acuity was uncommon. In view of this, MS-associ-
ated uveitis should be suspected in female patients with
bilateral uveitis, especially if pars planitis is present.
These patients often retain useful vision for many years
if treated.16
An association between MS during childhood and
uveitis is exceptionally rare. Jordan et al. (2003) re-
ported a female patient who presented at the age of 8
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years with bilateral intermediate uveitis and whose fi-
nal diagnosis of multiple sclerosis was made at age 21
years. Over 10 years these patient was treated systemi-
cally and underwent bilateral vitrectomy to reduce per-
manent side effects. Owing to good visual function and
low inflammatory signs, systemic therapy was stopped.
MS was diagnosed at the age of 21, after a 13-year his-
tory of uveitis and after 3 years without medication. In
the constellation of uveitis in childhood and later diag-
nosis of multiple sclerosis, the outlined therapy pro-
vided good functional results. Moreover, it may have de-
layed the manifestation of the underlying disease for 13
years.17
Optic neuritis
The term optic neuritis (ON) most often refers to the
optic neuropathy associated with demyelinating disease
(MS). ON is often the initial presentation of MS. Demye-
lating optic neuritis can be considered in three catego-
ries: acute, chronic or asymtpomatic (subclinical). Acute
optic neuritis is the most common form of optic neuritis.
Acute optic neuritis is characterized clinically by sud-
den loss of vision, usually in one eye but sometimes in
both eyes, and is associated with pain or discomfort
around the orbit or with eye movement. Pain may pre-
cede or occur concurrently with the visual loss. De-
creased acuity is the rule. The degree of visual loss var-
ies widely and is usually monocular, although a small
subgroup, particularly children, often have both eyes af-
fected simultaneously. Patients with unilateral acute
ON invariably have a relative afferent pupillary defect
(RAPD) in the affected eye (if the process is unilateral or
asymmetric) unless they have some type of related or
unrelated organic visual disturbance in the contrala-
teral eye.3,18,19
Acquired dyschromatopsia with the color deficit of-
ten being greater than the degree of visual acuity loss
and is of mixed red-green and blue-yellow type.20 Fla-
nagan and Zele (2004) reported that colour tresholds for
the observers with MS/ON were higher in the red-green
direction than blue-yellow direction, indicating greater
levels of red-green loss than blue-yellow loss. Achro-
matic tresholds were raised less than either red-green
or blue-yellow tresholds, showing less luminance-con-
trast loss than chromatic loss. These findings indicate
that demyelinating disease selectively reduces sensitiv-
ity to colour vision over luminance vision and red-green
colours over blue-yellow colours.21
Virtually any type of optic nerve visual field loss can
occur in optic neuritis, including altitudinal, arcuate,
central or cecocentral, diffuse,and even unilateral he-
mianopic visual field defects or asymmetric upper nasal
quadrantanopsia.22,23 Visual field defects are often
found in the contralateral eye. Contrast sensitivity im-
pairment is found in virtually all patients with optic
neuritis, usually parallels the severity of visual loss.24
The optic disc appears normal (retrobulbar ON) in about
two-thirds of patients. Optic disc swelling will be pres-
ent in 20 to 40% of cases or, if the patient has experi-
enced a previous clinical or subclinical attack of optic
neuritis, pale. Both the swelling and the pallor are non-
specific findings in ON, and neither is useful in dis-
tinguising demyelinating ON from the ON that may ac-
company other inflammatory or infectious diseases. The
degree of swelling does not correlate with the severity of
optic nerve disfunction. Optic disc or peripapillary hem-
orrhages are uncommon.
Magnetic resonance imaging (MRI) is the modality of
choice for investigating optic neuritis. MRI scanning of
the brain should be undertaken in all cases of acute ON
for diagnostic and prognostic purposes. The brain le-
sions of MS are commonly seen as T2 ovoid high-signal
white matter lesions on MR scans of the brain located in
periventricular regions perpendicular to ventricles with
variable enhancement.25 If the patient has a typical pre-
sentation of ON, an MRI need not be performed to ex-
clude a compressive lesion or to confirm the diagnosis.
An MRI can be performed to detect subclinical demy-
linating plaques to assist in determining the prognosis
for developing MS.
Beck et al. (2003) reported finding for the 10-year
risk of MS following an initiale episode of acute ON is
significantly higher if there is a single brain MRI lesion.
Higher numbers of lesions do not appreciably increase
that risk. However, even when brain lesions are seen on
MRI, more than 40% of the patients will not develop
clinical MS after 10 years. In the absence of MRI le-
sions, certain demographic and clinical features seem to
predict a very low likelihood of developing multiple scle-
rosis. This natural history information is a critical input
for estimating a patient,s 10-year multiple sclerosis risk
and for weighing the benefit of initiating prophylactic
treatment at the time of optic neuritis.26
For atypical presentations of optic neuritis, addi-
tional laboratory test, such as a cerebrospinal fluid
analysis, serologic tests, and visual evoked potentials,
prove to be useful in the diagnosis and subsequent man-
agement of the patient.25 For typical presentation of
ON, no serologic tests or cerebrospinal studies need to
be performed. Visual evoked potentials (VEP) are al-
most always abnormal, showing a prolonged latency on
the side of the affected optic nerve.27 Prolonged VEP la-
tency is quite a common but neither mandatory nor
pathognomonic finding in optic neuritis. The clinical im-
portance of VEP relies on its usefulness as a relatively
objective determinant of the visual pathway integrity,
however, clinical approach requires a combined diagnos-
tic procedure.
Natural history of acute ON is to worsen over several
days to 2 weeks end then to improve. Improvement
intially is rapid and starts approximately 3 weeks after
onset. Recovery of vision is nearly complete by 5 weeks
after onset. Improvement continues up to 1 year. Lana-
-Peixoto and Andrade reported (2001) that the clinical
features of childhood ON differ from those observed in
adults. In children is a better visual outcome and a
lower conversion rate to multiple sclerosis than in
adults.28
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There is no known treatment for acute demyeli-
nating optic neuritis.The use of a short course of intra-
venous corticosteroids (1g/day) for 3 days followed by a
2-week course of oral prednisone is associated with an
increase in the speed of recovery of vision, but the ulti-
mate visual function at 1 year and 5 years is the same as
it would be if no treatment were given.29,30 Oral predni-
sone alone, without prior treatment with high doses
methylprednisolone, may increase the risk for recurrent
ON and should be avoided.31
While it is clear that many patients with ON suffer
from a generalized disease of the central nervous sys-
tem that will go on to clinically definite MS, it is also
clear that others do not. As patients become increas-
ingly wellinformed and with the development of effec-
tive pharmacotherapy for MS, the distinction between
those patients with ON who have MS and those who do
not has become ever more important. Recent random-
ized clinical trials in patients with ON and evidence of
prior subclinical demyelination on MRI of the brain
found that treatment with recombinant interferon-beta-
-1a is beneficial in reducing the development of clini-
cally definite MS. Ophthalmologists should refer pa-
tients with acute ON suggestive of MS to a neurologist
for MS directed investigation.32,33 Chronic optic neuritis
is common. There is numerous MS patients who have no
history of acute visual loss, but who, nevertheles, com-
plain that the vision in one or both eyes is not normal an
who have evidence of unilateral or bilateral nerve dys-
function. Such patients my complaine of a slowly pro-
gressive loss of vision in one or both eyes or, complain of
blurred or distorted vision even though visual acuity is
1,0 in both eyes. Such patients have evidence of chronic
ON by clinical testing (e.g., visual fields, color vision,
contrast sensitivity) or electrophysiologic testing (VEPs).
Sometimes, slowly progressive visual loss are the first
symptom of the underlying MS.34
Asymptomatic or subclinical optic neuritis reported
in numerous patients with apparently unilateral ON in
their asymptomatic fellow eye. Many of these eyes also
had impairment of visual acuity, visual fields, color vi-
sion, and contrast sensitivity. It is important to note
that some of the subclinical findings in the contralateral
eye of a patient with acute ON may reflect concurrent
bilateral involvement. In the ONTT, visual fields fol-
lowed longitudinally showed new and different patterns
of defects over time, occasionally in both eyes.35 Asymp-
tomatic visual loss seems to be a universal feature of MS
and has a substantial impact on the visual pathways,
that it is present already at the time of clinical onset of
the disease, and that any progresion thereafter is slow
enough to elude detection during several years of fol-
low-up.36,37
Optic chiasmal and postchiasmal demyelinating
optic neuritis.
Demyelinating of the optic chiasm may produce optic
chiasmal syndrome characterized by a bitemporal vi-
sual field defect associated with varying degrees of loss
of visual acuity and color vision during the course of
well-documented MS, or it may be the initial manifesta-
tion of MS, preceding other neurologic signs and symp-
toms by weeks, months or even years.38 Demyelination
can occur anywhere along optic pathway, including the
optic tract, optic radiations, and striate cortex. Some pa-
tients with MS develop homonymous visual field defects
from demyelinating lesions of the postchiasmal visual
sensory pathways. The defect may be quadrantic or
hemianopic, complete or incomplete.39
Disorders of Ocular Motor System
Patients with multiple sclerosis may develop disor-
ders of fixation, ocular motility and ocular alignment.
Nystagmus is the most common disorder of fixation as-
sociated with MS, including upbeat nystagmus, down-
beat nystagmus, see-saw nystagmus, periodic alternating
nystagmus and convergence-induced pendular nystag-
mus.40 Jain et al. reported a 40-year-old patient with ac-
quired horizontal and vertical nystagmus and severe
oscillopsia secondary to multiple sclerosis had combined
treatment with gabapentin and a vertical Kestenbaum
type procedure. After gabapentin treatment (3,000 mg
orally daily) the horizontal nystagmus was significantly
reduced, and the patient developed a marked chin-up
position. The vertical nystagmus remained unchanged,
dampening on downgaze. A recession of both inferior
rectus muscles reduced the nystagmus significantly in
primary position, the abnormal head position disap-
peared, and oscillopsia completely resolved. Treatment
increased visual acuity from 6/24 in the right eye and
6/60 in the left eye to 6/9 in both eyes.41,42
Various saccadic intrusions – inappropriate saccades
that interfere with fixation – may occur in patients with
multiple sclerosis, including ocular flutter, opsoclonus,
and square-wave jerks. Clinical examination of eye mo-
vements, with attention to dynamic properties of sac-
cades and the vestibulo-ocular reflex, takes only a few
minutes to perform, but may provide better information
concerning the presence of brainstem and cerebellar in-
volvement.43,44 Prospective studies are required to de-
termine whether the development of abnormalities with
ocular motor testing are predicitive of disease activity
and progressive disability in MS.45
Disturbances of ocular motility or alignment may de-
velop during the course of MS, usually result from
demylinating lesions in the brainstem that affect su-
pranuclear, internuclear, nuclear, or fascicular path-
ways. Frohman et al. compared the accuracy of clinical
detection of internuclear ophthalmoparesis (INO) with
that of quantitative infrared oculograpy. Oculographic
techniques significantly enhance the precision of INO
detection to the clinical exam.44,46–49
Reche Sainz et al. (2002) presented a 38-year-old
woman with a episode of homonymus horizontal diplo-
pia at distance. She was orthophoric a near but had
esotropia at distance. Neurological evaluation was nor-
mal but multiple demyelinating lesions were shown in
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the magnetic resonance scan, with increased intrathe-
cal IgG production. Double vision improved after cor-
ticosteroid mega-doses.50
Conclusion
Patients with MS may develop disturbances of visual
sensory function and disorders of ocular motor system.
These disturbances may precede, or occur coincidentally
with neurologic manifestations. Sometimes, disturban-
ces of the visual sensory system are themselves asymp-
tomatic but may be important findings that establish
the diagnosis of MS in a patient with a single symptom-
atic neurologic deficit. Visual impairment occurs in nu-
merous patients with MS and may be the presenting
symptom. MRI scanning of the brain should be under-
taken in all cases of acute ON for diagnostic and prog-
nostic purposes. Disorders of ocular motor system are
frequently the initial sign of multiple sclerosis and occur
as its presenting sign weeks, month, or years before
other neurologic symptoms and signs develop. We em-
phasize that cooperation of neurologist and ophthalmol-
ogist plays an important role for clinical evaluation of
MS patients.
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NEUROOFTALMOLO[KE MANIFESTACIJE MULTIPLE SKLEROZE
S A @ E T A K
Autori pregledno prikazuju oftalmolo{ke manifestacije u bolesnika s multiplom sklerozom (MS), kako one koje
zahva}aju vizualni senzorni sustav tako i one koje zahva}aju o~ni motorni sustav. Poreme}aji vidne funkcije mogu
prethoditi, javiti se istodobno ili mogu pratiti neurolo{ke manifestacije. Poreme}aji vida nisu rijetki u bolesnika s MS
i obi~no nastaju uslijed akutne demijeliniziraju}e opti~ke neuropatije. Pa`ljiv pregled bolesnika s MS koji nikada nisu
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imali akutni opti~ki neuritis, mo`e otkriti asimptomatska o{te}enja vida. Ova asimptomatska o{te}enja vida ~ini se
da predstavljaju univerzalno obilje`je multiple skleroze. Bolesnici s multiplom sklerozom mogu razviti i poreme}aje
fiksacije, o~ne pokretljivosti i poreme}aje ravnote`e o~nih mi{i}a. Poreme}aj o~nog motornog sustava nerijetko je
inicijalni znak multiple skleroze i mo`e se manifestirati tjednima, mjesecima ili godinama prije drugih neurolo{kih
simptoma i znakova.
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